PTHS Pelthos Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1919246 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY-32.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin83.2%
Operating margin-101.6%
Net margin-152.2%
FCF margin-63.5%
EBITDA margin-98.9%
Returns
ROE-299.8%
ROA-61.2%
ROIC (approx.)-408.1%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio1.78x
Interest coverage-6.26x
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-35.9%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $15.39M | $15.60M | $10.91M | $9.39M | $7.41M | $0 | $0 | — |
| Cost of revenue | $1.66M | $3.61M | $1.67M | $1.67M | $2.32M | $0 | $0 | — |
| Gross profit | $13.73M | $11.99M | $9.23M | $7.72M | $5.09M | $0 | $0 | — |
| R&D expense | $1.02M | $600,000 | $186,000 | $374,000 | $145,000 | $515,000 | $194,000 | $285,000 |
| SG&A expense | $18.84M | $27.67M | $21.10M | $18.47M | $18.38M | $2.72M | $1.64M | $1.54M |
| Operating income | -$9.69M | -$17.32M | -$13.09M | -$12.00M | -$15.36M | -$3.23M | -$1.83M | -$1.82M |
| Interest expense | $2.27M | $2.39M | $2.35M | $1.31M | $1.35M | $218,000 | $134,000 | $108,000 |
| Pretax income | -$7.89M | -$23.42M | -$25.07M | -$28.59M | -$16.70M | -$3.45M | -$1.97M | -$1.93M |
| Income tax | $0 | $0 | $0 | -$6.92M | -$465,000 | $0 | $0 | — |
| Net income | -$7.89M | -$23.42M | -$25.07M | -$21.66M | -$16.24M | -$3.45M | -$1.97M | -$1.93M |
| EBITDA | -$9.41M | -$17.05M | -$12.62M | -$11.66M | -$14.97M | -$3.23M | -$1.83M | — |
| EPS (basic) | -2.04 | -6.62 | -7.57 | — | -5.30 | -5.29 | -3.21 | — |
| EPS (diluted) | -2.04 | -6.62 | -7.57 | — | -5.30 | -5.29 | -3.21 | — |
| Weighted avg. shares (diluted) | 3.86M | 3.54M | 3.31M | — | 3.06M | 651,921 | 612,889 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $17.69M | $24.19M | $31.98M | $17.97M | $14.20M | $59,000 | $131,000 | $513,000 |
| Receivables | $13.41M | $14.48M | $11.70M | $8.86M | — | — | — | $0 |
| Inventory | $21.47M | $21.47M | $23.42M | $23.57M | $24.10M | — | — | $0 |
| Current assets | $56.07M | $63.36M | $69.80M | $53.41M | $49.76M | $822,850 | $911,179 | $1.37M |
| PP&E, net | $8.51M | $8.88M | $9.31M | $9.59M | $10.17M | — | — | $0 |
| Goodwill | $24.68M | $24.68M | $24.68M | $24.68M | $30.62M | — | — | $0 |
| Intangibles | $36.34M | $37.40M | $38.44M | $39.47M | $32.52M | — | — | $0 |
| Total assets | $128.82M | $137.36M | $145.38M | $130.40M | $126.43M | $822,850 | $911,179 | $1.37M |
| Current liabilities | $31.43M | $31.96M | $25.00M | $25.99M | $24.77M | $7.32M | $5.11M | $4.08M |
| Total liabilities | $135.00M | $138.86M | $126.11M | $91.52M | $68.18M | $7.32M | $5.11M | $4.08M |
| Shareholders' equity | -$6.19M | -$1.50M | $19.27M | $38.88M | $58.25M | -$6.50M | -$4.20M | -$2.71M |
| Shares outstanding | 3.90M | 3.72M | 3.37M | 3.23M | 3.09M | 673,320 | 6.18M | 610,389 |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.16M | -$7.66M | -$13.13M | -$6.25M | -$15.26M | -$447,000 | -$632,000 | -$670,000 |
| Capital expenditure | $60,000 | $2,000 | $194,000 | $99,000 | $0 | $0 | $0 | — |
| Free cash flow | -$5.22M | -$7.67M | -$13.32M | -$6.35M | -$15.26M | -$447,000 | -$632,000 | — |
| Investing cash flow | -$60,000 | -$2,000 | -$194,000 | -$8.00M | $2.76M | $0 | $0 | — |
| Financing cash flow | -$1.17M | $0 | $27.52M | $18.02M | $26.69M | $375,000 | $250,000 | -$72,000 |
| Depreciation & amortization | $283,000 | $278,000 | $469,000 | $340,000 | $389,000 | $0 | $0 | — |
| Stock-based compensation | $1.94M | $2.76M | $1.91M | $1.80M | $2.81M | $394,000 | $486,000 | $530,000 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.